61 assets in Uveal Melanoma

Therapeutic assets addressing Uveal Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
c7r-gd2.cart cells Uveal Melanoma	Baylor College of Medicine	P1	CC (41)
Fludeoxyglucose Uveal Melanoma	Anusha Kalbasi	P1	CC (41)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Uveal Melanoma	Anusha Kalbasi	P1	CC (41)
Immunoglobulin G1 [De-236-Glycine,267-Glutamic Acid,De-C-Terminal Lysine], Anti-(Human Tumor Necrosis Factor Receptor Tnfrsf9) (Human-Mus Musculus Monoclonal Lvgn6051 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Lvgn6051 ?-Chain, Dimer Uveal Melanoma	M.D. Anderson Cancer Center	P1	CC (41)
Immunoglobulin G1 [De-236-Glycine,De-C-Terminal Lysine], Anti-(Human Cd40 Antigen) (Human Monoclonal Lvgn7409 ?1-Chain), Disulfide With Human Monoclonal Lvgn7409 ?-Chain, Dimer Uveal Melanoma	M.D. Anderson Cancer Center	P1	CC (41)
nn3201 Uveal Melanoma	Novelty Nobility, Inc.	P1	CC (41)
Pradusinstobart Uveal Melanoma	M.D. Anderson Cancer Center	P1	CC (41)
Ruxolitinib Uveal Melanoma	iOnctura	P1	CC (41)
Avelumab Uveal Melanoma	iOnctura	P1	CC (40)
Onm-501 Uveal Melanoma	OncoNano Medicine, Inc.	P1	NR ()
Tebentafusp-Tebn Uveal Melanoma	Thomas Jefferson University	P2	NR ()

Showing 51 to 61 of 61 assets

PreviousPage 2 of 2Next